Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Systematic Review of Molecular Biomarkers Predictive of Resistance to CDK4/6 Inhibition in Metastatic Breast Cancer
Uzma Asghar, Ruhi Kanani, Rebecca Roylance, et al.
JCO Precision Oncology (2022), Iss. 6
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

Circulating tumor DNA validity and potential uses in metastatic breast cancer
Ottavia Amato, Nefeli Giannopoulou, Michail Ignatiadis
npj Breast Cancer (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 17
Leveraging the replication stress response to optimize cancer therapy
Emily Cybulla, Alessandro Vindigni
Nature reviews. Cancer (2022) Vol. 23, Iss. 1, pp. 6-24
Open Access | Times Cited: 69
Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer
Claudette Falato, Francesco Schettini, Tomás Pascual, et al.
Cancer Treatment Reviews (2022) Vol. 112, pp. 102496-102496
Open Access | Times Cited: 41
Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
Andrew A. Davis, Jingqin Luo, Tiantian Zheng, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 9, pp. 1719-1729
Open Access | Times Cited: 29
CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective
Fiona H. Zhou, Teesha Downton, Allegra Freelander, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 25
AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers
Maysa Abu‐Khalaf, K. Alex Hodge, Christos Hatzis, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 23
Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer
Abhenil Mittal, Consolacion Molto Valiente, Faris Tamimi, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 2015-2015
Open Access | Times Cited: 23
Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers
Juliana Navarro-Yepes, Nicole M. Kettner, Xiayu Rao, et al.
Cancer Research (2023) Vol. 83, Iss. 19, pp. 3264-3283
Open Access | Times Cited: 23
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment
Antonino Glaviano, Seth A. Wander, Richard D. Baird, et al.
Drug Resistance Updates (2024) Vol. 76, pp. 101103-101103
Open Access | Times Cited: 14
Predictive biomarkers for personalized medicine in breast cancer
Sylvie Rodrigues-Ferreira, Clara Nahmias
Cancer Letters (2022) Vol. 545, pp. 215828-215828
Open Access | Times Cited: 34
Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy
Agnieszka K. Witkiewicz, Vishnu Kumarasamy, Ioannis Sanidas, et al.
Trends in cancer (2022) Vol. 8, Iss. 9, pp. 711-725
Open Access | Times Cited: 30
The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor–resistant ER + breast cancer with mitotic aberrations
Isabel Soria‐Bretones, Kelsie L. Thu, Jennifer Silvester, et al.
Science Advances (2022) Vol. 8, Iss. 36
Open Access | Times Cited: 30
HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study
Francesca Carlino, Anna Diana, Anna Ventriglia, et al.
Cancers (2022) Vol. 14, Iss. 20, pp. 4981-4981
Open Access | Times Cited: 29
Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer—A Review of the Literature
Ioana-Miruna Stanciu, Andreea Paroşanu, Cristina Orlov‐Slavu, et al.
Diagnostics (2023) Vol. 13, Iss. 5, pp. 987-987
Open Access | Times Cited: 21
Comprehensive Transcriptomic Analysis of EWSR1::WT1 Targets Identifies CDK4/6 Inhibitors as an Effective Therapy for Desmoplastic Small Round Cell Tumors
Justin W. Magrath, Shruthi Sanjitha Sampath, Dane A. Flinchum, et al.
Cancer Research (2024) Vol. 84, Iss. 9, pp. 1426-1442
Open Access | Times Cited: 8
CDKN2A/B homozygous deletion sensitizes IDH-mutant glioma to CDK4/6 inhibition
Ali M. Nasser, Lisa Melamed, Ethan A. Wetzel, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 14, pp. 2996-3005
Closed Access | Times Cited: 6
The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility
Gabriele Antonarelli, Beatrice Taurelli Salimbeni, Antonio Marra, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 192, pp. 104148-104148
Closed Access | Times Cited: 15
Cancer takes many paths through G1/S
Erik S. Knudsen, Agnieszka K. Witkiewicz, Seth M. Rubin
Trends in Cell Biology (2023) Vol. 34, Iss. 8, pp. 636-645
Closed Access | Times Cited: 15
An Italian Real-World Study Highlights the Importance of Some Clinicopathological Characteristics Useful in Identifying Metastatic Breast Cancer Patients Resistant to CDK4/6 Inhibitors and Hormone Therapy
Roberta Maltoni, Andrea Roncadori, William Balzi, et al.
Biomedicines (2024) Vol. 12, Iss. 3, pp. 498-498
Open Access | Times Cited: 5
A narrative review about CDK4/6 inhibitors in the setting of drug resistance: updates on biomarkers and therapeutic strategies in breast cancer
Shidi Zhao, Haochen Zhang, Na Yang, et al.
Translational Cancer Research (2023) Vol. 12, Iss. 6, pp. 1617-1634
Open Access | Times Cited: 12
Determinants of response to CDK4/6 inhibitors in the real-world setting
Agnieszka K. Witkiewicz, Emily Schultz, Jianxin Wang, et al.
npj Precision Oncology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 12
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors: existing and emerging differences
Stephen Johnston, Anna Emde, Carlos H. Barrios, et al.
JNCI Cancer Spectrum (2023) Vol. 7, Iss. 4
Open Access | Times Cited: 11
Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based Therapy
Thomas N. O’Connor, Emily Schultz, Jianxin Wang, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1749-1749
Open Access | Times Cited: 4
Effect of PR status on the prognosis of advanced ER-high HER2-negative breast cancer patients receiving CDK4/6 inhibitor combined with endocrine as first-line therapy
Lin Jia, Junning Peng, Nan Sun, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 4
Targeting ferroptosis resistance resensitizes metastatic HR+HER2− breast cancer cells to palbociclib‐hormone therapy
Charles Pottier, Laetitia Montero‐Ruiz, Robin Jehay, et al.
Cancer Communications (2025)
Open Access
Page 1 - Next Page

Scroll to top